66.18
前日終値:
$67.22
開ける:
$66.53
24時間の取引高:
3.00M
Relative Volume:
0.99
時価総額:
$12.53B
収益:
$2.83B
当期純損益:
$-1.02B
株価収益率:
-12.01
EPS:
-5.51
ネットキャッシュフロー:
$194.14M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+14.60%
6か月 パフォーマンス:
+24.21%
1年 パフォーマンス:
+24.33%
Exact Sciences Corp Stock (EXAS) Company Profile
EXAS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EXAS
Exact Sciences Corp
|
66.18 | 12.74B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
572.41 | 212.64B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
209.94 | 148.81B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
708.45 | 56.99B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.74 | 41.81B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.46 | 35.91B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-01-02 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-08-02 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-05-10 | アップグレード | Craig Hallum | Hold → Buy |
| 2023-05-05 | 開始されました | UBS | Neutral |
| 2023-03-09 | アップグレード | Citigroup | Neutral → Buy |
| 2023-02-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2021-11-03 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 繰り返されました | BTIG Research | Buy |
| 2021-07-29 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-29 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-29 | 繰り返されました | Stifel | Buy |
| 2021-06-15 | 開始されました | Raymond James | Strong Buy |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Equal Weight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-29 | ダウングレード | UBS | Buy → Neutral |
| 2020-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-04-02 | 開始されました | Evercore ISI | Outperform |
| 2020-01-10 | 再開されました | BTIG Research | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Dougherty & Company | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-17 | 繰り返されました | BofA/Merrill | Buy |
| 2019-10-01 | 再開されました | Craig Hallum | Buy |
| 2019-09-26 | 開始されました | Oppenheimer | Outperform |
| 2019-02-26 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-09 | 開始されました | UBS | Buy |
| 2018-09-05 | 再開されました | The Benchmark Company | Hold |
| 2018-08-13 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-01-29 | 開始されました | Goldman | Neutral |
| 2018-01-08 | 繰り返されました | The Benchmark Company | Buy |
| 2017-11-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | ダウングレード | BTIG Research | Buy → Neutral |
すべてを表示
Exact Sciences Corp (EXAS) 最新ニュース
Exact Sciences announces results from ALTUS study - TipRanks
Exact Sciences (EXAS) Is Up 6.3% After Oncoguard Liver Test Outperforms Ultrasound in ALTUS Study - Yahoo Finance
Exact Sciences' Blood Test Detects Liver Cancer Far Earlier Than Standard Ultrasound - Nasdaq
EXAS Unveils Promising Results from ALTUS Study with Oncoguard L - GuruFocus
Exact Sciences’ liver cancer blood test shows superior early detection - Investing.com
Exact Sciences blood test shows improved liver cancer detection - StreetInsider
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test - Business Wire
Herriott James, Exact Sciences Corp SVP, sells $105k in stock - Investing.com Canada
Baranick, Exact Sciences EVP, sells $200k in EXAS stock - Investing.com
Exact Sciences (EXAS) Gets a Hold from UBS - The Globe and Mail
Why Exact Sciences Corporation stock remains on buy listsWeekly Trend Recap & Weekly Consistent Profit Watchlists - fcp.pa.gov.br
How Exact Sciences Corporation stock performs in weak economy2025 Bull vs Bear & Daily Volume Surge Signals - newser.com
Why Exact Sciences Corporation stock could see breakout soonJuly 2025 Sector Moves & AI Driven Price Forecasts - fcp.pa.gov.br
Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarter - newser.com
Exact Sciences Corporation stock chart pattern explainedTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Leading vs lagging indicators on Exact Sciences Corporation performance2025 Analyst Calls & Risk Managed Investment Signals - newser.com
EXAS Stock Quote Price and Forecast - CNN
Key facts: Exact Sciences raises 2025 revenue forecast to $3.23B; Wells Fargo boosts price target to $85 - TradingView
Exact Sciences (NASDAQ:EXAS) Trading 8.1% Higher After Better-Than-Expected Earnings - MarketBeat
EXAS: Wells Fargo Raises Price Target to $85.00, Maintains Overw - GuruFocus
Is Exact Sciences Corporation stock a buy for dividend growthJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2025 Earnings Call Transcript - Insider Monkey
Exact Sciences to Participate in November 2025 Investor Conference - BioSpace
Exact Sciences Corp Faces Regulatory Risks Amid Potential Government Disruptions - TipRanks
Why Exact Sciences Stock Blasted Higher on Tuesday - The Motley Fool
Why Exact Sciences Stock Blasted Higher on Tuesday - Nasdaq
Exact Sciences Corp Reports Strong Q3 Earnings - TipRanks
Barclays Maintains Exact Sciences (EXAS) Overweight Recommendation - Nasdaq
Key facts: Exact Sciences Q3 Revenue Hits $850.7M; Cancerguard Launched; Analysts Raise Price Targets - TradingView
EXAS: TD Cowen Raises Price Target to $90 on Buy Rating | EXAS S - GuruFocus
Exact Sciences (EXAS) Receives Updated Analyst Rating from Baird - GuruFocus
EXAS: Benchmark Raises Price Target to $75 in Latest Analyst Rev - GuruFocus
EXAS: Guggenheim Raises Price Target to $75 While Maintaining Bu - GuruFocus
Stifel raises Exact Sciences stock price target to $80 on strong Cologuard growth - Investing.com Canada
EXAS: Barclays Raises Price Target to $77, Maintains Overweight Rating | EXAS Stock News - GuruFocus
These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga
Madison-based Exact Sciences reports Q3 results topping analysts’ expectations - Wisconsin State Journal
EXAS Q3 Deep Dive: Cologuard Plus, Care Gap Programs, and New Test Launches Drive Growth - Yahoo! Finance Canada
EXAS: Stifel Raises Target Price to $80, Maintains Buy Rating | - GuruFocus
BTIG Raises Price Target for Exact Sciences (EXAS) to $85 | EXAS Stock News - GuruFocus
Exact Sciences stock price target raised to $85 from $75 at BTIG - Investing.com
Exact Sciences to Participate in November Investor Conference - Bluefield Daily Telegraph
Exact Sciences: Q3 Earnings Snapshot - theheraldreview.com
How Intuitive Surgical Stock Gained 19.5% Last Month - AOL.com
Canaccord Genuity raises Exact Sciences stock price target to $85 on strong growth - Investing.com
Exact Sciences Corp (EXAS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp (EXAS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Exact Sciences Reports Record Q3 Revenue and Raises Guidance - TipRanks
Transcript : Exact Sciences Corporation, Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Exact Sciences Q3 2025 slides: 20% revenue growth, guidance raised - Investing.com
Exact Sciences Corp (EXAS) 財務データ
収益
当期純利益
現金流量
EPS
Exact Sciences Corp (EXAS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Nov 04 '25 |
Sale |
70.08 |
2,858 |
200,289 |
22,368 |
大文字化:
|
ボリューム (24 時間):